BioSpace News Archive

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s cash tender offer for Forty Seven, Inc. expired at 11:59 p.m. on March 27, 2020.

New Site in Sarasota, FL, Increases Akron’s US Manufacturing Capacity for Cell and Gene Therapy Materials and Technologies

Pulsara Patient allows clinicians to instantly and securely connect with patients or their family members via live audio and video calling, a capability that is especially pertinent for outpatient medical isolation during the COVID-19 pandemic

The U.S. Food and Drug Administration has been providing unprecedented flexibility to labs and manufacturers to develop and offer COVID-19 tests across the U.S.

The Largest Women’s and Family Telemedicine Provider Provides Access to 24/7 On-demand Care for 1.8 Million Massachusetts Residents

ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the “Company”), a leading integrated solutions provider in the rapidly growing non-medical health and wellness market in China, today announced its preliminary unaudited financial data for the fourth quarter and the full year ended December 31, 2019.

The Alzheimer’s Association is offering new guidance to help ensure the delivery of high-quality care for people living with Alzheimer’s and all dementia in long-term care and community-based settings during the current COVID-19 crisis.

nnovent Biologics, Inc. (“Innovent” or “the Company”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality innovative medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today announced its financial results for the full year ended December 31, 2019 and corporate progress.

Junshi Biosciences (HKEX: 1877) today announced that the U.S. Food and Drug Administration (FDA) has recently granted Orphan Drug Designation (ODD) for toripalimab in combination with Pfizer’s axitinib for the treatment of patients with mucosal melanoma

Agilent Technologies, Inc. filed a supplement to its proxy statement with the Securities and Exchange Commission announcing a change of location for its previously adjourned annual meeting of stockholders.